科拓生物 reported revenue of ¥0.17B for the period ended 2026-06-30, +3.8% year on year. Net income was ¥0.03B, a 14.8% net margin on a 47.1% gross margin. The largest revenue line is 食用益生菌制品 at 75% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.17B | +3.8% |
| Gross profit | ¥0.08B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.03B | -39.1% |
| Gross margin | 47.1% | Net margin 14.8% |
| Revenue Q/Q | -0.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 食用益生菌制品 | ¥0.13B | 74.6% |
| 动植物微生态制剂 | ¥0.03B | 19.8% |
| 复配食品添加剂 | ¥0.01B | 5.5% |
| 益生菌技术服务 | ¥0.00B | 0.1% |
| 其他 | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.09B | 52.9% |
| R&D | ¥0.02B | 13.1% |
| SG&A | ¥0.04B | 22.1% |
| Tax & other | ¥0.00B | 1.3% |
| Item | Amount |
|---|---|
| Total assets | ¥2.03B |
| Total liabilities | ¥0.24B |
| Shareholders' equity | ¥1.79B |
| Equity / assets | 88.4% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | 40% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
西域旅游 ・ 锋尚文化 ・ 美畅股份 ・ 蓝盾光电 ・ 卡倍亿 ・ 南大环境 ・ 大宏立 ・ 圣元环保 ・ 杰美特 ・ 康泰医学 ・ 欧陆通 ・ 回盛生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies